39.31 USD
+1.04 (+2.72%)
39.31 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 87% to NAMS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 47.55. This target is 20.96% above the current price.
NAMS was analyzed by 21 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about NAMS.
In the previous month the buy percentage consensus was at a similar level.
NAMS was analyzed by 21 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-06 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-05 | Needham | Maintains | Buy -> Buy |
| 2025-10-17 | Citigroup | Maintains | Buy -> Buy |
| 2025-08-25 | Wells Fargo | Initiate | Overweight |
| 2025-08-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-07-17 | Goldman Sachs | Initiate | Neutral |
| 2025-06-17 | Citigroup | Initiate | Buy |
| 2025-06-12 | Needham | Reiterate | Buy -> Buy |
| 2025-06-10 | Stifel | Initiate | Buy |
| 2025-05-08 | Needham | Maintains | Buy -> Buy |
| 2025-04-08 | Needham | Reiterate | Buy -> Buy |
| 2025-02-27 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-02-27 | Needham | Maintains | Buy -> Buy |
| 2025-01-28 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-01-24 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-01-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-30 | HC Wainwright & Co. | Initiate | Buy |
| 2024-12-11 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-12-05 | Needham | Reiterate | Buy -> Buy |
| 2024-11-21 | Needham | Reiterate | Buy -> Buy |
| 2024-11-11 | Needham | Reiterate | Buy -> Buy |
| 2024-11-07 | Needham | Reiterate | Buy -> Buy |
| 2024-09-23 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-09-05 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-28 | Needham | Initiate | Buy |
| 2024-07-30 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-06-07 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-05-15 | TD Cowen | Initiate | Buy |
| 2024-03-14 | ScotiaBank | Initiate | Sector Outperform -> Sector Outperform |
| 2024-03-13 | ScotiaBank | Initiate | Sector Outperform |
NEWAMSTERDAM PHARMA CO NV / NAMS FAQ
What is the price target for NAMS stock?
21 analysts have analysed NAMS and the average price target is 47.55 USD. This implies a price increase of 20.96% is expected in the next year compared to the current price of 39.31.
How do analysts rate NEWAMSTERDAM PHARMA CO NV (NAMS)?
The consensus rating for NEWAMSTERDAM PHARMA CO NV (NAMS) is 86.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed NEWAMSTERDAM PHARMA CO NV (NAMS)?
The number of analysts covering NEWAMSTERDAM PHARMA CO NV (NAMS) is 21.